Previous close | 0.0900 |
Open | 0.1800 |
Bid | 0.0400 |
Ask | 0.2600 |
Strike | 200.00 |
Expiry date | 2023-06-16 |
Day's range | 0.1800 - 0.1800 |
Contract range | N/A |
Volume | |
Open interest | 128 |
AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
AbbVie Inc. ( NYSE:ABBV ) shareholders have seen the share price descend 13% over the month. But don't let that...
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.